Try our Advanced Search for more refined results

Carefirst of Maryland, Inc., et al. v. Johnson & Johnson, et al.

  1. December 16, 2025

    Va. Judge Advances Most Claims In Stelara Antitrust Case

    A Virginia federal judge has allowed health insurer CareFirst's anticompetition and patent fraud claims against Johnson & Johnson to move forward in a case alleging anticompetitive behavior in relation to the immunosuppressive drug Stelara, while letting the pharmaceutical giant escape some claims of misrepresentation.

  2. November 06, 2025

    CareFirst Urges Ban On J&J Character Talk At Stelara Trial

    Health insurer CareFirst is asking a Virginia federal judge to bar Johnson & Johnson from promoting its "good character" to a jury that will weigh class claims of anticompetitive conduct and patent fraud to extend market protection on the blockbuster autoimmune drug Stelara.

  3. March 06, 2024

    J&J Seeks Exit From Suit Over Stelara Exclusivity

    Johnson & Johnson told a Virginia federal court Tuesday it shouldn't have to face a proposed class action claiming it has been trying to stifle competition in the market for the immunosuppressive drug Stelara, saying there was no "scheme" to enforce its patents as the suit alleges.

  4. December 08, 2023

    J&J Hit With Suit Over Stelara Exclusivity

    A group of Blue Cross and Blue Shield licensees has filed a lawsuit in Virginia federal court claiming Johnson & Johnson has been trying to stifle competition in the market for the immunosuppressive drug Stelara, saying it defrauded federal patent officials.